PHAT analyst estimates

Phathom Pharmaceuticals (PHAT) analyst ratings, the average price target and its range, and every firm's latest call.

PHAT analyst ratings and price targets

DateFirmCallTarget
Oct 21, 2026Craig-HallumPhathom Pharmaceuticals price target lowered to $15 from $20 at Craig-Hallum$15.00
Oct 14, 2026JefferiesPhathom Pharmaceuticals (PHAT) PT Lowered to $16 at Jefferies$16.00
Sep 9, 2026Leerink PartnersPhathom Pharmaceuticals initiated with a Market Perform at Leerink$10.00
Aug 14, 2026BarclaysPhathom Pharmaceuticals price target lowered to $14 from $18 at Barclays$14.00
Jul 31, 2026GuggenheimPhathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim$22.00
Jul 31, 2026Craig-HallumPhathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum$20.00
Jul 30, 2026NeedhamPhathom Pharmaceuticals price target lowered to $22 from $28 at Needham$22.00
Mar 27, 2026BarclaysPhathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays$18.00
Feb 26, 2026Stifel NicolausStifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)$28.00
Dec 11, 2025Raymond JamesPhathom Pharmaceuticals initiated with a Strong Buy at Raymond James$28.00
Dec 8, 2025BarclaysPhathom Pharmaceuticals initiated with an Equal Weight at Barclays$16.00
Oct 31, 2025H.C. WainwrightPhathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright$26.00
Oct 31, 2025Craig-HallumPhathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum$22.00
Oct 30, 2025GuggenheimPhathom Pharmaceuticals (PHAT) PT Raised to $20 at Guggenheim$20.00
Mar 7, 2025GuggenheimPhathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim$18.00

Updated 2026-11-03 04:19 UTC